Biodesix offers analysis and consultative services for clients wanting to evaluate our ProTS Platform or who want to have specific proteomics mass spectrometry analysis performed by our world class experts. Project data confidentiality is ensured throughout the entire project workflow. Collaborations provide a more cost effective way to utilize Biodesix’s proprietary platform than the Company’s service offerings. See Services

The Company is currently engaged in multiple collaborations with clinical and research partners (University of Colorado Health Sciences Center, Vanderbilt University Medical Center, M. D. Anderson, Hospitale San Raffaele, Italy, University Clinics Innsbruck Austria, University Clinic of Nijmegen, Netherlands, the NCI, the Biotherapy Development Agency). The Company carefully selects projects by technical feasibility, sample availability, and clinical and commercial value.

A typical collaborative project starts with a discussion with the clinical investigators. If this is successful, and an agreement is reached on contractual terms, the Company continues with a small pilot study. The purpose of the pilot study is to assess the quality of the mass spectra from the specific biological samples, to assess mass spec reproducibility, and to obtain first hints for differentiating patterns. The results of a successful pilot study are discussed with the Biodesix commercial team, and a decision is made to enter the diagnostic discovery phase. In this phase an appropriately sized training set is used to optimize a classifier. Following classifier identification, the classifier is further validated on a fully blinded test set. Should this be successful, additional validation is undertaken by attempting to obtain retrospectively available samples from multiple institutions. Only if all of these steps are successful, and the commercial value of a specific diagnostic has been confirmed, does the Company proceed to product development and commercialization. This staged approach allows our collaborations to minimize discovery cost and risk and thus enables our clinical partners to explore a variety of clinical questions that are of importance to them.